Saturday, September 6, 2025
  • Advertise
  • Recruitment
  • Contact us:
  • Register
Irish Pharmacy News
  • News
    • Latest
    • Community Pharmacy
  • Learning
    • CPD
    • Features
    • Team Training
    • Research
  • Magazines
  • OTC
    • OTC Awards
    • Product News
  • Awards
    • Irish Pharmacy Awards 2024
    • Awards News
  • HPN
  • Log In
  • Register
No Result
View All Result
  • News
    • Latest
    • Community Pharmacy
  • Learning
    • CPD
    • Features
    • Team Training
    • Research
  • Magazines
  • OTC
    • OTC Awards
    • Product News
  • Awards
    • Irish Pharmacy Awards 2024
    • Awards News
  • HPN
  • Log In
  • Register
No Result
View All Result
Irish Pharmacy News

A new drug approved for the Irish market is set to help menopausal women beat debilitating hot flushes, experts say.

Robyn Maginnis by Robyn Maginnis
30 April 2024
in News
0
A new drug approved for the Irish market is set to help menopausal women beat debilitating hot flushes, experts say.

Loretta Dignam, founder and CEO of The Menopause Hub

Veoza is a non-hormonal medication designed to stop hot flushes and night sweats and will be fully available here in April.

Campaigners have branded the daily tablet a ‘game-changer’ which offers women an alternative to hormone replacement therapy (HRT) for the dreaded menopause symptoms.

“Veoza is a hugely positive development for those in perimenopause and menopause,” said Loretta Dignam, CEO and founder of the Menopause Hub.

“A UK study concluded that women experience a weekly total of 17 hot flushes and 11 night sweats – and this symptom alone can impact severely on sleep, mood, concentration, work and personal lives.

“I personally endured up to 39 hot flushes a day and then more at night with the duvet on and off over a three-year period so I know first-hand how debilitating they can be, so this will be a game-changer.

“Up to 80% of some 652,000 Irish women suffer symptoms of menopause, primarily hot flushes and night sweats which are triggered by low oestrogen levels, affecting the part of the brain that regulates body temperature.

“Veoza offers another option to women who can’t take HRT for various medical reasons or for those whose bodies won’t absorb the hormones.”

Ms Dignam said that at present the drug is not covered under the Drug Payment Scheme so it will be available privately at a cost of up to €70 per month.

But her clinics are looking forward to Veoza being eventually approved for public funding as soon as possible.

“The non-hormonal medication was presented at all three of my clinics in Dublin and Cork during the week and our staff are looking forward to being able to offer it to more women who are suffering these devitalising sweats.”

The one-a-day tablet was recently approved for use in Ireland by the Health Products Regulatory Authority (HPRA).

Clinical trials in Europe found that after one month of treatment, the number of moderate to severe daily hot flushes was cut by 53% on average for participants.

It is not approved yet for those with active breast cancer.

The Menopause Hub is Ireland’s first dedicated clinic devoted to treating menopausal and perimenopausal symptoms and, has offices in Mount Merrion, South Dublin, Santry, North Dublin and Ballincollig, Co. Cork. 

The clinics have treated more than 10,000 patients in Ireland since opening in 2019.

Tags: IrelandIrish Pharmacy NewsPharmacyWomen's Health
Previous Post

Management in Pharmacy of Allergic Rhinitis

Next Post

Astellas’ Veoza™ (fezolinetant) now available in Ireland for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause

Next Post
Astellas’ Veoza™ (fezolinetant) now available in Ireland for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause

Astellas’ Veoza™ (fezolinetant) now available in Ireland for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause

Four UCD researchers receive ERC Starting Grants for groundbreaking research projects

Four UCD researchers receive ERC Starting Grants for groundbreaking research projects

4 September 2025
EUROPEAN COMMISSION AUTHORISES TWICE-YEARLY LENACAPAVIR FOR HIV  PREVENTION (brand name YEYTUO®) 

EUROPEAN COMMISSION AUTHORISES TWICE-YEARLY LENACAPAVIR FOR HIV  PREVENTION (brand name YEYTUO®) 

4 September 2025
Back to school: Expert guidance from the HSE for a smoother start to the school year

Back to school: Expert guidance from the HSE for a smoother start to the school year

22 August 2025

RECOMMENDED NEWS

Partnership

Pharmacy Strategic Partnership

1 year ago
Raising awareness of Haemochromatosis

Raising awareness of Haemochromatosis

1 year ago
New Boots for Stephen

New Boots for Stephen

5 years ago
Sligo Pharmacist Hilary Dolan Shortlisted for The People’s Pharmacist of the Year 2021

Sligo Pharmacist Hilary Dolan Shortlisted for The People’s Pharmacist of the Year 2021

4 years ago
Tweets by Irish_PharmNews

Quick links

  • About
  • Advertise
  • Careers
  • Contact us

Other info

  • Contact us
  • Register for Digital Magazines
  • Privacy Policy
  • About
  • Advertise
  • Careers
  • Contact us

© 2024 IPN

  • Login

    Forgot password? | Register

    Register

    Registration confirmation will be emailed to you.

    Login | Forgot password?

    Reset Password

    Please enter your username or email address. You will receive a link to create a new password via email.

    Login

Login

Register

Forgotten Password?

Register | Lost your password?
| Back to Login
No Result
View All Result
  • News
  • Learning
  • Other
    • Conferencing
    • Developments
    • Product News
    • Profiles
    • Research
  • Digital Magazines (IPN Online Issues Older Issue Tabs)
  • Awards

© 2024 IPN